Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Monday, June 30, 2014

Biotech Media Advisory: GenSpera (OTCQB:GNSZ) 2014 BIO International Presentation Available

SAN ANTONIO - June 30, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, CA.

Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study for lead drug candidate, G-202.
Summary:
  • G-202 Data in Hepatocellular (HCC) Patients (Ph I and Ph II)
  • All patients previously progressed on, or were intolerant of, sorafenib
  • Outstanding clinical safety profile
  • Well tolerated with easily managed and predictable side effects
  • No effect on bone marrow!
  • 80% of patients with stable disease (no tumor growth) at two months
  • 50% of patients with stable disease for ≥ 4 months
  • Long-term disease stabilization (≥ 9 months) in 15% of patients
  • One patient remains on treatment > 22 months
  • End of bone pain in one patient with vertebral metastasis
The full BIO presentation is available for view at: http://www.genspera.com/press/140620_GNSZ_BIO_Presentation_June_24_2014.pdf
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
About BIO
The 2014 BIO International Convention was held June 23-26 at the San Diego Convention Center in San Diego, California.
The BIO International Convention was hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. http://convention.bio.org/2014/
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
Contact:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.
210-479-8112
Investors:
John Baldissera
BPC Financial Marketing
800-368-1217
Media: (800) 665 0411
Disclaimer/ Disclosure:Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18,2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Wednesday, June 25, 2014

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Online Access to Infectious Disease and Cancer Therapy Presentation

SAN DIEGO - June 25, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19th, is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at http://aethlonmedical.investorroom.com/index.php?s=19. Once the page has been launched, click on the "listen to the webcast" icon.

Investorideas.com Newswire The presentation covered the following topics:
  • A status report on the first FDA approved study of Hemopurifier therapy in the United States, including Aethlon's clinical progression strategy to advance infectious disease and oncology treatment indications.
  • A review of clinical safety data and efficacy observations resulting from Hemopurifier administration to HIV and Hepatitis c (HCV) infected individuals.
  • The results of government and non-government collaborative testing programs against category "A" bioterror and pandemic threats, including pandemic influenza, dengue, ebola, pox viruses, and other viral pathogens that remain untreatable with drug or vaccine therapies.
  • The discovery that the Aethlon Hemopurifier captures tumor-secreted exosomes underlying a broad-spectrum of cancer indications and the resulting patent protection already issued to protect Aethlon's cancer treatment endeavors.
  • A review of a National Cancer Institute (NCI) sponsored publication that references Aethlon Medical as the first organization with a therapeutic candidate to address tumor-secreted exosomes.
  • A review of recent landmark discoveries that tumor-secreted exosomes suppress the immune system of cancer patients, seed the creation and spread of metastasis, promote angiogenesis, and transport PD-1, PDL-1, VEGF, CTLA-4, EGRF and other primary cancer therapeutic targets of the biopharmaceutical industry.
  • The central role of the Aethlon Hemopurifier in the rapidly emerging immuno-oncology industry, which analysts expect to grow to $35 billion per year in the near future.
  • The recent launch of Aethlon's Exosome Sciences diagnostic subsidiary, which is the first organization to demonstrate the ability to isolate exosomes that transport diagnostic biomarkers underlying alzheimer's disease (AD), chronic traumatic encephalopathy (CTE), and glioblastoma multiforme (GBM) that have crossed through blood brain barrier into the circulatory system. Thus, setting the stage for liquid biopsies that allow for the identification and monitoring of these disease conditions.
About Aethlon Medical
Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com or www.ExosomeSciences.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Get free news alerts: Sign up here
Disclaimer/ Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Tuesday, June 24, 2014

Breaking Biotech News: GenSpera (OTCQB:GNSZ) Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202

SAN ANTONIO - June 24, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at 11:15 PDT, in San Diego, CA.

Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study in hepatocellular (HCC) patients who had previously progressed on, or who were intolerant of, sorafenib. Historically, this patient population has a median time to progression of only two months when they enter subsequent clinical trials. Impressively, 80% of patients treated with G-202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study.
Commenting on the Phase I and II data of G-202 in HCC Patients, Dr. Dionne stated, "Our lead candidate, G-202, is demonstrating better than expected clinical results and safety profile. These data are strongly encouraging and highly suggestive of clinical activity in this very challenging patient population. Relative to other drugs currently in advanced trials in HCC patients, G-202 appears to exhibit a better tolerated side effect profile and a larger subset of patients who experience disease stabilization of at least six months. Remarkably, one patient remains on treatment 22 months after initiation of treatment and another patient experienced complete remission of bone pain due to a metastatic lesion to the spinal column. As a result of these data, we are designing a randomized study as the next step toward United States Food and Drug Administration approval of G-202."
Investors can view the company presentation at the Company website: http://www.genspera.com
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma.
For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
About BIO
The 2014 BIO International Convention is June 23-26 at the San Diego Convention Center in San Diego, California.
The BIO International Convention is hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. http://convention.bio.org/2014/
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
Contact:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.
210-479-8112
Investors:
John Baldissera
BPC Financial Marketing
800-368-1217
Media: (800) 665 0411
Disclaimer/ Disclosure:Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18,2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Monday, June 23, 2014

Breaking Biotech News: GenSpera, Inc. (OTCQB:GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer"

SAN ANTONIO - June 23, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202.

The video explains, "The thapsigargin plant, a weed that grows abundantly in the Mediterranean, kills by disruption of the calcium balance in cells, all cells. Now, Genspera has targeted its active ingredient thapsigargin, to kill only the cells we select: cancer."
Chairman and CEO, Craig Dionne, PhD. says, "We have taken the powerful toxin thapsigargin and found a way to keep it inactive until it finds the cells it has been programmed to seek. Then it releases its active ingredient and destroys all of the targeted cells."
In the case of GenSpera's first drug, G-202, this target is PSMA, an enzyme which is only found on the walls of the blood vessels that feed cancer tumors, regardless of the type of cancer.
See the Video: http://youtu.be/jULjEul-mBk
Chairman and CEO, Craig Dionne, PhD., will be presenting at the 2014 BIO International Convention on Tuesday, June 24th at 11:15 PDT in San Diego, CA, where he will be providing an update on G-202. The Company's BIO presentation will be available on June 24th to investors.
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma.
For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
Contact:
Company:
GenSpera, Inc.
Craig Dionne, PhD, 210-479-8112
CEO
Investors:
BPC Financial Marketing
John Baldissera, 800-368-1217
Disclaimer/ Disclosure:Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18,2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Thursday, June 19, 2014

Breaking Biotech News: GenSpera (OTCQB:GNSZ) CEO, Craig Dionne, to Present Update on Lead Drug Candidate G-202 at 2014 Bio International Convention

SAN ANTONIO - June 19, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the 2014 BIO International Convention, on Tuesday, June 24th, at 11:15 PDT, in San Diego, CA (http://mybio.org/search/all?terms=GenSpera). Dr. Dionne will give an update of the ongoing G-202 Phase II trials in both hepatocellular carcinoma and glioblastoma patients and discuss upcoming milestones, as well as deliver a general GenSpera overview.

The Company will release the BIO presentation and update to investors following the June 24th session.
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma.
About BIO
The 2014 BIO International Convention is June 23-26 at the San Diego Convention Center in San Diego, California.
The BIO International Convention is hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
http://convention.bio.org/2014/
For more information, please visit the Company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
Contact:
Company:
GenSpera, Inc.
Craig Dionne, PhD, 210-479-8112
CEO
Investors:
BPC Financial Marketing
John Baldissera, 800-368-1217
Disclaimer/ Disclosure:Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18,2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Tuesday, June 17, 2014

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) to Present at The Wall Street Analyst Forum

SAN DIEGO - June 17, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will present at The Wall Street Analyst Forum 25th Annual Institutional Investor Conference on Thursday, June 19th, at 12:05 PM EDT. Mr. Joyce's presentation will include an update on a forthcoming FDA-cleared study of the Aethlon Hemopurifier®, a review of the Company's cancer programs, and a progress report on Exosome Sciences, Inc., a diagnostic subsidiary recently launched by the Company.

Investorideas.com Newswire A live webcast of Mr. Joyce's Wall Street Analyst Forum presentation can be accessed at the following URL: www.visualwebcaster.com/event.asp?id=99587
The Wall Street Analyst Forum will take place June 19, 2014 at the University Club of New York, One West 54th Street, New York, NY.
About Aethlon Medical
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
About The Wall Street Analyst Forum
The Wall Street Analyst Forum has conducted 80+ multiday/multitrack analyst conferences in which over 2500 different NYSE/NASDAQ/AMEX/OTC companies have presented and over 2,000 different institutions have attended in Boston, New York and London since 1989. Public companies ranging from General Electric, Microsoft Corp., Mattel Inc., Pfizer Inc., Kinross Gold to Genzyme have presented. Institutions ranging from Fidelity Management, Wellington Management, MFS Investment Management, Pioneer Investment Management, Putnam Management have attended.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Monday, June 16, 2014

Biodefense Q&A: PositiveID's (OTCBB: PSID) Chairman and CEO Discusses Progress with Bio-Threat Detection Technology and Revenue Guidance

New York, NY - June 16, 2014 (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Mr. William J. Caragol, Chairman and Chief Executive Officer of PositiveID Corporation (OTCBB: PSID), a developer of biological detection and diagnostics solutions. Mr. Caragol discusses the current status and opportunities for its bio-threat detection technology and recently announced revenue guidance.

Q: Investorideas.com
On May 27 th you released a corporate update on your contracts for M-BAND and Firefly technologies. Can you give investors the highlights?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We are very proud of what we have achieved so far in 2014. Our major accomplishments include forming significant partnerships with commercial and federal government organizations, and importantly, revenue generation. In summary, we entered into a contract with a large commercial partner to support a U.S. Department of Defense (“DoD”) contract and test our M-BAND system, which will provide revenue to the Company of $841,000 through September; we announced one of our teaming partners was awarded a prime contract by the U.S. Defense Threat Reduction Agency to conduct research and development to combat weapons of mass destruction; and, more recently, we signed a Space Act Agreement with NASA’s Ames Research Center through which NASA will assess our Firefly technology for potential ground and space applications. When you look back at our releases, the commercial and government partners we are working with are a true “who’s who” in the fields of security and detection.
Q: Investorideas.com
At this point do you see more interest in your M-BAND or Firefly Technologies for contracts and revenue streams and can you give some insight as to why?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We continue to see interest in both M-BAND and Firefly. M-BAND, which stands for Microfluidic Bio-agent Autonomous Networked Detector, has more of a targeted, albeit significant, opportunity through anticipated multi-billion dollar government programs to detect airborne biological weapons of mass destruction. On the other hand, we believe Firefly, our point-of-need, handheld, molecular diagnostic device, will be able to be used in a multitude of industries, including military/government applications, healthcare and even agricultural applications. As you might expect, these are very large markets as well.
Q: Investorideas.com
Your latest press release on June 11th announced your first ever revenue guidance of $4-10 million. You also stated that $3.3 million is backlogged. This is obviously a transitional period for the company in several ways. Are you starting to see a perception change from the financial community?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
I think we are. We are seeing more interest from strategic partners who see the potential of our products and the markets we are pursuing. The fact that we are generating revenue from a large commercial partner under a government contract and technology license is also noteworthy. We have the ability to execute, our technology and IP portfolio is strong, and we believe we have the partners in place to win major contracts.
Q: Investorideas.com
As a small company receiving contracts from large government agencies including U.S. Department of Defense, U.S. Department of Homeland Security, and Department of Health and Human Services do you attribute your success to the technology or your partnering or both?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
I think our partners are a direct reflection of the quality and differentiators of our technology and the strength and experience of our management team. We are very gratified by the partnerships we’ve established and believe they provide an important validation of what PositiveID has to offer.
Q: Investorideas.com
In May you announced signing a Space Act Agreement with NASA's Ames Research Center to collaborate on testing the Company's Firefly Dx detection system ("Firefly") as a platform for biological research and commercial development for ground and space applications. Can you give our readers the significance of this collaboration and what it means moving forward?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
When an organization with the respect and recognition that NASA has earned wants to work with you and further the development of your technology to see how it may help them in their specific endeavors, it is significant. As we pursue opportunities with other government and commercial entities, having a group like NASA standing by our side makes people take notice. Having third-party support, especially when it comes from a group of world-class scientists, is very important for a small company like PositiveID.
Q: Investorideas.com
In closing, it seems like the company and technology are gaining momentum and traction from some very high profile institutions and agencies; do you think that is a reflection of a renewed sense of urgency to address bio-threats or is it a matter of going through the system and reaping the long term rewards?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Unfortunately, we’ve witnessed global events that underscore the danger posed by biological weapons of mass destruction. That said, there definitely is a heightened focus on the need for bio-threat detection, and a pick-up in government procurements for these technologies. At the same time, however, it’s not simply a matter of being in the right place at the right time. We have worked diligently to create the necessary partnerships to successfully capture the opportunities ahead of us.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.PositiveIDCorp.com .
Contact
PSID: 
Allison Tomek 
561-805-8000 
atomek@positiveidcorp.com
InvestorIdeas.com is a global news source and research resource covering leading sectors including defense and biodefense, social media, tech, biotech, water, mining and energy.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for free news alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp . Disclosure: Investorideas has been previously compensated by PSID in the form of cash and 144 restricted shares for participation in the security conference in March plus news p;ublication.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Statements about PositiveID's future expectations, including without limitation, the likelihood that PositiveID will generate revenue of $4-10 million over the next 18 months, $3.3 million of which is already in backlog; the likelihood that Firefly will be able to be used in a multitude of industries, including military/government applications, healthcare and even agricultural applications; the likelihood that PositiveID has the partners in place to win major contracts; the likelihood that PositiveID has created the necessary partnerships to successfully capture the opportunities ahead of it; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including the likelihood that PositiveID will be successful with its submissions for bids and proposals in conjunction with several large commercial partners in response to a pick-up in new U.S. government procurements for bio-threat detection, and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 11, 2014, and 10-Qs filed on May 20, 2014, November 19, 2013, and August 14, 2013, as amended August 19, 2013, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

New York, NY - June 16, 2014 (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Mr. William J. Caragol, Chairman and Chief Executive Officer of PositiveID Corporation (OTCBB: PSID), a developer of biological detection and diagnostics solutions. Mr. Caragol discusses the current status and opportunities for its bio-threat detection technology and recently announced revenue guidance.
Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner
Q: Investorideas.com
On May 27 th you released a corporate update on your contracts for M-BAND and Firefly technologies. Can you give investors the highlights?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We are very proud of what we have achieved so far in 2014. Our major accomplishments include forming significant partnerships with commercial and federal government organizations, and importantly, revenue generation. In summary, we entered into a contract with a large commercial partner to support a U.S. Department of Defense (“DoD”) contract and test our M-BAND system, which will provide revenue to the Company of $841,000 through September; we announced one of our teaming partners was awarded a prime contract by the U.S. Defense Threat Reduction Agency to conduct research and development to combat weapons of mass destruction; and, more recently, we signed a Space Act Agreement with NASA’s Ames Research Center through which NASA will assess our Firefly technology for potential ground and space applications. When you look back at our releases, the commercial and government partners we are working with are a true “who’s who” in the fields of security and detection.
Q: Investorideas.com
At this point do you see more interest in your M-BAND or Firefly Technologies for contracts and revenue streams and can you give some insight as to why?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We continue to see interest in both M-BAND and Firefly. M-BAND, which stands for Microfluidic Bio-agent Autonomous Networked Detector, has more of a targeted, albeit significant, opportunity through anticipated multi-billion dollar government programs to detect airborne biological weapons of mass destruction. On the other hand, we believe Firefly, our point-of-need, handheld, molecular diagnostic device, will be able to be used in a multitude of industries, including military/government applications, healthcare and even agricultural applications. As you might expect, these are very large markets as well.
Q: Investorideas.com
Your latest press release on June 11th announced your first ever revenue guidance of $4-10 million. You also stated that $3.3 million is backlogged. This is obviously a transitional period for the company in several ways. Are you starting to see a perception change from the financial community?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
I think we are. We are seeing more interest from strategic partners who see the potential of our products and the markets we are pursuing. The fact that we are generating revenue from a large commercial partner under a government contract and technology license is also noteworthy. We have the ability to execute, our technology and IP portfolio is strong, and we believe we have the partners in place to win major contracts.
Q: Investorideas.com
As a small company receiving contracts from large government agencies including U.S. Department of Defense, U.S. Department of Homeland Security, and Department of Health and Human Services do you attribute your success to the technology or your partnering or both?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
I think our partners are a direct reflection of the quality and differentiators of our technology and the strength and experience of our management team. We are very gratified by the partnerships we’ve established and believe they provide an important validation of what PositiveID has to offer.
Q: Investorideas.com
In May you announced signing a Space Act Agreement with NASA's Ames Research Center to collaborate on testing the Company's Firefly Dx detection system ("Firefly") as a platform for biological research and commercial development for ground and space applications. Can you give our readers the significance of this collaboration and what it means moving forward?  
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
When an organization with the respect and recognition that NASA has earned wants to work with you and further the development of your technology to see how it may help them in their specific endeavors, it is significant. As we pursue opportunities with other government and commercial entities, having a group like NASA standing by our side makes people take notice. Having third-party support, especially when it comes from a group of world-class scientists, is very important for a small company like PositiveID.
Q: Investorideas.com
In closing, it seems like the company and technology are gaining momentum and traction from some very high profile institutions and agencies; do you think that is a reflection of a renewed sense of urgency to address bio-threats or is it a matter of going through the system and reaping the long term rewards?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Unfortunately, we’ve witnessed global events that underscore the danger posed by biological weapons of mass destruction. That said, there definitely is a heightened focus on the need for bio-threat detection, and a pick-up in government procurements for these technologies. At the same time, however, it’s not simply a matter of being in the right place at the right time. We have worked diligently to create the necessary partnerships to successfully capture the opportunities ahead of us.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.PositiveIDCorp.com .
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
InvestorIdeas.com is a global news source and research resource covering leading sectors including defense and biodefense, social media, tech, biotech, water, mining and energy.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for free news alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp . Disclosure: Investorideas has been previously compensated by PSID in the form of cash and 144 restricted shares for participation in the security conference in March plus news p;ublication.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Statements about PositiveID's future expectations, including without limitation, the likelihood that PositiveID will generate revenue of $4-10 million over the next 18 months, $3.3 million of which is already in backlog; the likelihood that Firefly will be able to be used in a multitude of industries, including military/government applications, healthcare and even agricultural applications; the likelihood that PositiveID has the partners in place to win major contracts; the likelihood that PositiveID has created the necessary partnerships to successfully capture the opportunities ahead of it; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including the likelihood that PositiveID will be successful with its submissions for bids and proposals in conjunction with several large commercial partners in response to a pick-up in new U.S. government procurements for bio-threat detection, and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 11, 2014, and 10-Qs filed on May 20, 2014, November 19, 2013, and August 14, 2013, as amended August 19, 2013, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Investorideas.com 800-665-0411
- See more at: http://www.investorideas.com/CO/PSID/news/2014/06161.asp#sthash.9G7QPnmw.dpuf
New York, NY - June 16, 2014 (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Mr. William J. Caragol, Chairman and Chief Executive Officer of PositiveID Corporation (OTCBB: PSID), a developer of biological detection and diagnostics solutions. Mr. Caragol discusses the current status and opportunities for its bio-threat detection technology and recently announced revenue guidance.
Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner
Q: Investorideas.com
On May 27 th you released a corporate update on your contracts for M-BAND and Firefly technologies. Can you give investors the highlights?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We are very proud of what we have achieved so far in 2014. Our major accomplishments include forming significant partnerships with commercial and federal government organizations, and importantly, revenue generation. In summary, we entered into a contract with a large commercial partner to support a U.S. Department of Defense (“DoD”) contract and test our M-BAND system, which will provide revenue to the Company of $841,000 through September; we announced one of our teaming partners was awarded a prime contract by the U.S. Defense Threat Reduction Agency to conduct research and development to combat weapons of mass destruction; and, more recently, we signed a Space Act Agreement with NASA’s Ames Research Center through which NASA will assess our Firefly technology for potential ground and space applications. When you look back at our releases, the commercial and government partners we are working with are a true “who’s who” in the fields of security and detection.
Q: Investorideas.com
At this point do you see more interest in your M-BAND or Firefly Technologies for contracts and revenue streams and can you give some insight as to why?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We continue to see interest in both M-BAND and Firefly. M-BAND, which stands for Microfluidic Bio-agent Autonomous Networked Detector, has more of a targeted, albeit significant, opportunity through anticipated multi-billion dollar government programs to detect airborne biological weapons of mass destruction. On the other hand, we believe Firefly, our point-of-need, handheld, molecular diagnostic device, will be able to be used in a multitude of industries, including military/government applications, healthcare and even agricultural applications. As you might expect, these are very large markets as well.
Q: Investorideas.com
Your latest press release on June 11th announced your first ever revenue guidance of $4-10 million. You also stated that $3.3 million is backlogged. This is obviously a transitional period for the company in several ways. Are you starting to see a perception change from the financial community?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
I think we are. We are seeing more interest from strategic partners who see the potential of our products and the markets we are pursuing. The fact that we are generating revenue from a large commercial partner under a government contract and technology license is also noteworthy. We have the ability to execute, our technology and IP portfolio is strong, and we believe we have the partners in place to win major contracts.
Q: Investorideas.com
As a small company receiving contracts from large government agencies including U.S. Department of Defense, U.S. Department of Homeland Security, and Department of Health and Human Services do you attribute your success to the technology or your partnering or both?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
I think our partners are a direct reflection of the quality and differentiators of our technology and the strength and experience of our management team. We are very gratified by the partnerships we’ve established and believe they provide an important validation of what PositiveID has to offer.
Q: Investorideas.com
In May you announced signing a Space Act Agreement with NASA's Ames Research Center to collaborate on testing the Company's Firefly Dx detection system ("Firefly") as a platform for biological research and commercial development for ground and space applications. Can you give our readers the significance of this collaboration and what it means moving forward?  
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
When an organization with the respect and recognition that NASA has earned wants to work with you and further the development of your technology to see how it may help them in their specific endeavors, it is significant. As we pursue opportunities with other government and commercial entities, having a group like NASA standing by our side makes people take notice. Having third-party support, especially when it comes from a group of world-class scientists, is very important for a small company like PositiveID.
Q: Investorideas.com
In closing, it seems like the company and technology are gaining momentum and traction from some very high profile institutions and agencies; do you think that is a reflection of a renewed sense of urgency to address bio-threats or is it a matter of going through the system and reaping the long term rewards?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Unfortunately, we’ve witnessed global events that underscore the danger posed by biological weapons of mass destruction. That said, there definitely is a heightened focus on the need for bio-threat detection, and a pick-up in government procurements for these technologies. At the same time, however, it’s not simply a matter of being in the right place at the right time. We have worked diligently to create the necessary partnerships to successfully capture the opportunities ahead of us.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.PositiveIDCorp.com .
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
InvestorIdeas.com is a global news source and research resource covering leading sectors including defense and biodefense, social media, tech, biotech, water, mining and energy.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for free news alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp . Disclosure: Investorideas has been previously compensated by PSID in the form of cash and 144 restricted shares for participation in the security conference in March plus news p;ublication.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Statements about PositiveID's future expectations, including without limitation, the likelihood that PositiveID will generate revenue of $4-10 million over the next 18 months, $3.3 million of which is already in backlog; the likelihood that Firefly will be able to be used in a multitude of industries, including military/government applications, healthcare and even agricultural applications; the likelihood that PositiveID has the partners in place to win major contracts; the likelihood that PositiveID has created the necessary partnerships to successfully capture the opportunities ahead of it; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including the likelihood that PositiveID will be successful with its submissions for bids and proposals in conjunction with several large commercial partners in response to a pick-up in new U.S. government procurements for bio-threat detection, and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 11, 2014, and 10-Qs filed on May 20, 2014, November 19, 2013, and August 14, 2013, as amended August 19, 2013, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Investorideas.com 800-665-0411
- See more at: http://www.investorideas.com/CO/PSID/news/2014/06161.asp#sthash.9G7QPnmw.dpuf

Tuesday, June 10, 2014

Medical Technology News: Medical Technology The Role of Aethlon Medical (OTCQB: AEMD) in the Emerging Immuno-Oncology Market; Q&A with Aethlon Chairman and CEO, Jim Joyce

Point Roberts, WA, NEW YORK, NY - June 10, 2014 (Investorideas.com newswire) Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a Q&A interview with Mr. James A. Joyce ,Chairman and CEO of Aethlon Medical, Inc. (OTCBB:AEMD).

Q: Investorideas.com
How did Aethlon Medical become involved in cancer research?
A: James A. Joyce, Chairman, CEO
Several years ago, we made a bet that particles known as exosomes, were released by tumors to suppress the immune system of cancer patients. We believed that exosomes triggered the death of the immune cells you need to combat cancer. That cancer deployed exosomes as a mechanism to survive and proliferate. It is important to recognize that when we initiated our exosome research programs, the medical community viewed these particles as nothing more than cellular debris with no biological function.
Our second bet was that our Hemopurifier, the same Hemopurifer that has been utilized in the treatment of HIV and hepatitis c infected individuals, could capture tumor-secreted exosomes underlying a wide range of cancers. As it turns out, we were right on both accounts. Exosomes suppress the immune system and can be captured by our Hemopurifier. As a result, we are positioned to address a significant unmet medical need in cancer care. However, to leverage our opportunity in cancer we needed a market for immune-based therapies to emerge. Fortunately, the growing interest in immune-based therapies has now triggered an Immuno-Oncology industry explosion.
Q:Investorideas.com
Can you describe the Immuno-Oncology industry?
A: James A. Joyce ,Chairman, CEO
The Immuno-Oncology industry is based on therapies that augment or train the immune system to better combat cancer. The long-term goal of the Immuno-Oncology industry is to eliminate the need for toxic chemotherapy and radiation in cancer care. In fact, I suspect mankind will someday look back in disbelief at the barbaric use of chemo and radiation. Regardless, huge bets are being made that Immuno-Oncology will revolutionize the cancer field. Analysts at Citigroup predict the Immuno-Oncology market, which basically didn't exist two years ago, will reach $35 billion per year. This prediction is further reinforced by the fact that Merck, Bristol-Myers, AstraZeneca and Roche alone have already initiated more than 78 immune-based clinical studies.
Q:Investorideas.com
What Immuno-Oncology role do you feel Aethlon Medical will play?
A: James A. Joyce ,Chairman, CEO
We believe Hemopurifier therapy should play a central role in the Immuno-Oncology marketplace. Especially if you consider that as a device, our Hemopurifier can be combined to improve the benefit of other therapies without adding drug toxicity. It's not hard to envision that the elimination of tumor-secreted exosomes from circulation would improve the ability for immune-based drugs to combat cancer. From a mechanistic standpoint, combining a drug that stimulates the immune response with a device that inhibits immune-suppression would seem to be the perfect therapeutic marriage.
Q:Investorideas.com
Why are tumor-secreted exosomes an important cancer therapy target?
A: James A. Joyce ,Chairman, CEO
Last month, researchers from Harvard, Massachusetts General and Oxford published an article that discussed why tumor-secreted exosomes are cancer therapy targets. The article referenced the current knowledge that exosomes promote cancer progression by suppressing the immune system. However, that's just the beginning as the researchers also pointed to evidence that exosomes trigger resistance to drug therapies, that they play a role in allowing tumors to create their own blood supply for survival, and that they are seeds that allow for the creation and spread of cancer metastasis. The article also validated another original belief of ours; that the level of tumor-secreted exosomes in circulation correlates with the stage of cancer progression. In other words, if you don't have cancer, tumor-secreted exosomes won't be present. However, if you have advanced-stage cancer, they will be present in massive quantities. Based on this knowledge, it’s possible that circulating exosome load will someday become an industry standard for monitoring cancer progression in much the same way circulating viral load is the standard for monitoring infectious disease progression. Regardless, the article only referenced one company with a therapeutic strategy to address tumor-secreted exosomes. That was Aethlon Medical. Oh, and by the way, the authors of the article were sponsored by the National Cancer Institute.
Q:Investorideas.com
Is there anything else about tumor-secreted exosomes that we should know?
A: James A. Joyce ,Chairman, CEO
Yes, tumor-secreted exosomes have been discovered to transport PD-1, which is perhaps the most important target of drug companies advancing immuno-oncology therapies. In fact, the latest scientific literature seems to suggest that exosomes may be providing a transport mechanism for many pharmaceutical industry targets as a means for them to proliferate below the surveillance of the immune system.
Q:Investorideas.com
Based on the opportunity in cancer care, are you moving away from the infectious disease market?
A: James A. Joyce ,Chairman, CEO
The rapidly emerging opportunity in cancer allows us to expand the utility of Hemopurifier therapy. It does not replace our infectious disease endeavors, which is evidenced by plans to launch the first FDA approved study of Hemopurifier therapy in hepatitis c (HCV) patients. We believe that drug resistance and viral mutation will continue to drive opportunities for us in the HIV and HCV space and we also recognize that the proven broad-spectrum capabilities of Hemopurifier therapy provides a backdrop to address viral pathogens that remain untreatable with drug or vaccine therapies. However, I won't be surprised if it’s our ability to capture tumor-secreted exosomes that drives broad awareness of Hemopurifier therapy among both the medical and investment community.
About Aethlon Medical .( OTCBB:AEMD ).and Jim Joyce:
Aethlon Medical creates therapeutic devices to address infectious disease, cancer and other life-threatening conditions. The Company's lead product is the Aethlon Hemopurifier®, an extracorporeal device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes. Jim Joyce is the founder, Chairman and CEO of Aethlon Medical.
http://www.aethlonmedical.com/
About Investorideas.com ( www.investorideas.com )
InvestorIdeas.com is a global news source and research resource covering leading sectors including medical technology, biotech, defense, water, mining and energy.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for free news alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program ( 9700 per Year, paid quarterly) for news publishing .
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Contact Investorideas.com 800 665 041

Monday, June 9, 2014

Biotech News Alert: SUNSHINE BIOPHARMA'S (OTCQB: SBFM) Adva-27a FEATURED IN 2014 WORLDWIDE UTERINE CANCER REPORT FOR ITS EFFECTIVENESS AGAINST MULTIDRUG RESISTANT UTERINE CANCER CELLS

Montreal, Quebec, Canada - June 9, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma, Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that Adva-27a, the Company’s flagship oncology drug candidate was featured in Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014 Report for its effectiveness against multidrug resistant uterine cancer cells in vitro.

The Global Markets Direct Uterine Cancer Report provides comprehensive information on the therapeutic development for Uterine Cancer, with comparative analysis, therapeutics assessment, mechanism of action, route of administration and molecule type.  The Report also reviews key players involved in the therapeutic development for Uterine Cancer including Sunshine Biopharma Inc.
In December 2012, Sunshine Biopharma announced that it had achieved dramatic effects in Uterine Cancer using its Adva-27a compound. The studies were carried out in MES-SA/Dx5, a Uterine Sarcoma cell line that has become multidrug resistant through the use of a commonly administered chemotherapy drug, Doxorubicin.  Adva-27a was able to efficiently kill these cells with an IC50 of less than 8 micromolar, a pharmacologically very favorable drug concentration.
In addition to Uterine Cancer, Adva-27a has been shown to be effective at killing multidrug resistant Breast Cancer cells, Small-Cell Lung Cancer cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).
Sunshine Biopharma recently reported that it has initiated the construction of mouse xenograft models for Pancreatic Cancer as part of the plans of positioning Adva-27a for clinical development for Pancreatic Cancer in parallel with the previously announced multidrug resistant Breast Cancer indication. The first U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.
"We are very pleased that this testing indicated that our drug, Adva-27a, is effective against Uterine Cancer," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "In the U.S. alone, over 52,000 new cases of Uterine Cancer are diagnosed each year. "We are anxious to begin our clinical studies soon and look forward to the opportunity of providing a new treatment for Uterine Cancer patients worldwide," he added.
About The Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014 Report
The following links provide more information about the Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014:
http://www.globalmarketsdirect.com/Report.aspx?ID=Uterine-Cancer-Pipeline-Review-H1-2014&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
http://www.researchandmarkets.com/research/9bk98l/uterinecancer
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.